Exact Sciences, a molecular diagnostics company, reported a net loss per share of USD 0.72 for Q4 2022, beating analysts’ expectations of USD 0.84. Revenue for the quarter grew 17% YoY to USD 553 million, also beating analyst consensus by 4.7%. Net losses for the quarter were reduced by 42% YoY to USD 127.7 million. Revenue for the full year increased by 18% YoY to USD 2.1 billion and net losses for the year declined by 25% YoY to USD 624 million. The total, cumulative number of people that tested for cancer passed 12 million for the year, including ten million with Cologuard.
The increase in revenue in Q4 2022 was mainly attributed to a 45% YoY increase in screening revenue, while precision oncology revenue and Covid-19-testing revenues reported a 4% and 87% YoY decline, respectively.
The gross profit margin declined to 73% in Q4 2022 in comparison to 75% in Q4 2021. Operating expenses declined 3% YoY due to lower sales and marketing expenses (down 26% YoY) which was offset by higher general administration expenses (up 8% YoY) and higher cost of sales (up 24% YoY) compared to Q4 2021. The adjusted EBITDA significantly improved to USD 4.9 million for the quarter, from a loss of USD 115 million in Q4 2021.
Cash and cash equivalents and marketable securities stood at USD 0.6 billion at the end of December 2022, decreasing from USD 0.7 billion in December 2021. Exact Science increased its earnings guidance for 2023, expecting revenue of USD 2.27 billion–USD 2.31 billion, implying a 9.1%–11.1% YoY increase.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.